In the field of cancer liquid biopsy, mainstream Circulating Tumor Cell (CTC) detection technologies currently on the market are mostly limited to screening or small-scale culture of “conventional CTCs.” Constrained by insufficient cell yield, they are often forced to rely on “organoid models”—requiring cost-prohibitive imaging systems and statistical software for predictive analysis, which rarely yields clear, definitive conclusions. Furthermore, Circulating Hybrid Cells (CHCs), which hold even higher research and clinical value, remain a universally acknowledged obstacle for in vitro expansion among top global laboratories.
The CELLSRUN® technology platform has successfully shattered this international bottleneck. It pioneers an approach that eliminates the need for expensive microfluidic instrumentation, cumbersome screening steps, and complex in vitro chemical fusion. Instead, it enables the direct and simultaneous expansion of both conventional CTCs and highly challenging CHC populations straight from patient peripheral blood.
Powered by our patented culture technology, we generate massive yields of functional, dual-cell populations. This not only overcomes the chronic pain point of low cell counts in traditional testing, but also flawlessly preserves the patient's authentic genetic heterogeneity and immune microenvironment imprinting. By removing exorbitant cost barriers, CELLSRUN® truly translates cutting-edge academic discoveries into scalable, real-world drug screening applications for “precision avatar medicine.”
Breaking through market limitations that only process conventional CTCs, we simultaneously culture and successfully expand rare CHC cells—universally acknowledged in academia as the most difficult cells to proliferate in vitro.
Generating massive cell yields, our technology completely resolves the industry pain point of relying on organoid models and repetitive predictive testing due to insufficient cell counts, significantly elevating test reliability and stability.
Eliminating the need for expensive microfluidic instruments and tedious isolation steps commonly required on the market, our patented culture technology enables highly efficient primary culture directly from peripheral blood.
Leveraging abundant dual-cell populations without high imaging costs, we reliably screen nearly 100 drugs to deliver personalized drug response data, empowering medical teams to make precise clinical decisions.
Our versatile platform delivers patient-specific efficacy data for physicians, assists nutraceutical manufacturers with formulation functional testing, and supports pharma R&D—serving as the ultimate platform for personalized medicine.
Featuring high scalability, our patented platform comprehensively covers testing across immune cells, circulating tumor cells, and specialized functional stem cells, driving multi-dimensional personalized healthcare.
Breaking free from the timeframe constraints of organoid models, our technology delivers precise drug screening reports in just 14 working days, saving precious time for patient treatment windows.